In an aggregate cohort of prostate cancer patients largely based in institutions located in Western countries, the frequency of FOXA1 mutations among patients with primary disease was approximately 8-9% while among patients with metastatic disease, the frequency of FOXA1 mutations rose to between 12 and 13% (36). This evidence concerns the gene FOXA1 and prostate carcinoma.